Dignitana AB
STO:DIGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Dignitana AB
Total Equity
Dignitana AB
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
D
|
Dignitana AB
STO:DIGN
|
Total Equity
kr4.3m
|
CAGR 3-Years
-44%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
-17%
|
|
|
Elekta AB (publ)
STO:EKTA B
|
Total Equity
kr8B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
CellaVision AB
STO:CEVI
|
Total Equity
kr887.6m
|
CAGR 3-Years
11%
|
CAGR 5-Years
16%
|
CAGR 10-Years
17%
|
|
|
Getinge AB
STO:GETI B
|
Total Equity
kr29.4B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Arjo AB (publ)
STO:ARJO B
|
Total Equity
kr7.5B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
S
|
Stille AB
STO:STIL
|
Total Equity
kr708.7m
|
CAGR 3-Years
55%
|
CAGR 5-Years
45%
|
CAGR 10-Years
31%
|
|
Dignitana AB
Glance View
Dignitana AB engages in the development, manufacture and marketing of medical technology systems related to medical cooling. The company is headquartered in Lund, Skane. The company went IPO on 2009-06-18. The company develops, manufactures and markets a medical device primarily used for scalp cooling in order to eliminate or reduce chemotherapy induced hair loss. The firm focuses on the product DigniCap, which counteracts hair loss during chemotherapy. The product is a cold cap, which when put on the patient’s head, lowers the temperature of the scalp. The low temperature reduces perfusion, delivery of blood and metabolism. The reduced blood flow results in a smaller amount of chemotherapy available for uptake in the cells, while the decreased temperature results in less absorption and reduced effects of chemotherapy. These factors together reduce the risk of hair loss. The DigniCap scalp cooling system is patented in Europe, Japan and the United States. The company has a subsidiary BrainCool AB, which focuses on producing different models of brain cooling for stroke and cardiac arrest patients.
See Also
What is Dignitana AB's Total Equity?
Total Equity
4.3m
SEK
Based on the financial report for Mar 31, 2025, Dignitana AB's Total Equity amounts to 4.3m SEK.
What is Dignitana AB's Total Equity growth rate?
Total Equity CAGR 10Y
-17%
Over the last year, the Total Equity growth was 59%. The average annual Total Equity growth rates for Dignitana AB have been -44% over the past three years , -36% over the past five years , and -17% over the past ten years .
